Elucid has raised US$55 million in an oversubscribed series D financing, with the funding to support the commercialisation of its artificial intelligence (AI)-powered cardiovascular imaging platform.
The round brings Elucid’s total funding raised to date to approximately $185 million and includes new participation from a large medtech company, Elucid said in a press release.
Proceeds from the financing will be used to accelerate commercial expansion of Elucid’s clinical platform, including fractional flow reserve derived from computed tomography (FFRCT)—510(k) submission currently under US Food and Drug Administration (FDA) review—and Plaque-IQ, as well as investment in clinical studies.
The company is preparing for full commercial launch with FDA clearance of its 510(k) submission for its BioIntegrated FFRCT product that is designed to offer high accuracy and reproducibility compared to invasive FFR.
Alongside its FDA-cleared Plaque-IQ, Elucid intends for FFR-CT—together with a novel user interface and reporting workflow—to form a comprehensive clinical decision platform. Plaque-IQ is the only FDA-cleared, non-invasive method capable of quantifying the highest-risk plaque type and plaque composition in coronary and carotid arteries with accuracy validated against histopathology.
“Analogous to oncology’s shift from population-based, one-size treatment, Elucid is applying AI to integrate anatomy, biology, and physiology to bring personalised treatment to coronary artery disease management. Physician feedback indicating that our current platform can uniquely lead to better care decisions fuels our mission to predict and personalize the prevention of heart attacks and strokes,” said Kelly Huang, CEO of Elucid.
